Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.25

Benzinga Newsdesk www.benzinga.com Positive 84.5%

Neg 0% Neu 0% Pos 84.5%

Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $9 to $9.25.